臨床外科79巻9号

2024年09月発行

特集 徹底解説　大腸癌治療ガイドライン2024 詳説

進行再発切除不能癌の治療戦略

著者： 安藤健樹¹ 對馬隆浩¹ 山﨑健太郎¹

所属機関： ¹静岡県立静岡がんセンター消化器内科

ページ範囲：P.1012 - P.1015

【ポイント】
◆マイクロサテライト不安定性（MSI）/ミスマッチ修復（MMR）機能検査が推奨された．
◆HER2陽性大腸癌に対して推奨される検査・薬物療法が追記された．
◆後方治療において，FTD/TPI＋ベバシズマブが新たに推奨された．
◆TMB-high大腸癌に対してはペムブロリズマブ投与を検討することが追記された．

参考文献

1）Le DT, Uram JN, Wang H, et al：PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372：2509-2520, 2015

2）Le DT, Kim TW, Van Cutsem E, et al：Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer：KEYNOTE-164. J Clin Oncol 38：11-19, 2020

3）Diaz LA Jr, Shiu KK, Kim TW, et al：Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer（KEYNOTE-177）：final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23：659-670, 2022

4）André T, Shiu KK, Kim TW, et al：Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 383：2207-2218, 2020

5）Overman MJ, McDermott R, Leach JL, et al：Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142）：an open-label, multicentre, phase 2 study. Lancet Oncol 18：1182-1191, 2017

6）Overman MJ, Lonardi S, Wong KYM, et al：Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36：773-779, 2018

7）Andre T, Elez E, Van Cutsem E, et al：Nivolumab（NIVO）plus ipilimumab（IPI）vs chemotherapy（chemo）as first-line（1L）treatment for microsatellite instability-high/mismatch repair-deficient（MSI-H/dMMR）metastatic colorectal cancer（mCRC）：First results of the CheckMate 8HW study. J Clin Oncol 42（3 suppl）：LBA768, 2024

8）Richman SD, Southward K, Chambers P, et al：HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer：analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238：562-570, 2016

9）Nakamura Y, Okamoto W, Kato T, et al：Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer：a phase 2 trial. Nat Med 27：1899-1903, 2021

10）Baselga J, Cortés J, Kim SB, et al：Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366：109-119, 2012

11）Grothey A, Van Cutsem E, Sobrero A, et al：Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）：an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381：303-312, 2013

12）Mayer RJ, Van Cutsem E, Falcone A, et al：Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372：1909-1919, 2015

13）Kuboki Y, Nishina T, Shinozaki E, et al：TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies（C-TASK FORCE）：an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol 18：1172-1181, 2017

14）Pfeiffer P, Yilmaz M, Möller S, et al：TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer：an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21：412-420, 2020

15）Prager GW, Taieb J, Fakih M, et al：Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 388：1657-1667, 2023

16）Doebele RC, Drilon A, Paz-Ares L, et al：Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours：integrated analysis of three phase 1-2 trials. Lancet Oncol 21：271-282, 2020

17）Hong DS, DuBois SG, Kummar S, et al：Larotrectinib in patients with TRK fusion-positive solid tumours：a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21：531-540, 2020

18）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer：Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38：1-10, 2020